TICKERNERD
Menu
ELANELANHealthcare · Drug Manufacturers - Specialty & Generic

ELAN Stock Forecast: Elanco Animal Health, Inc. Price Predictions for 2026-2027

Last close, 14 Aug 2026
$24
+5.15% on the day

The 17 Wall Street analysts covering Elanco Animal Health, Inc. hold a median 12-month price target of $32 — +33.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 98 of 100 as at 15 Aug 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$11.8B
Ticker Nerd rank
98 / 100
Median analyst target
$32
Analysts covering
17
Total return, dividends reinvested
1W
+7.0%
1M
−7.4%
YTD
+4.6%
1Y
+31.5%
From 52W high
−11.8%
From 52W low
+36.4%
$17
$27
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ELAN stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Elanco Animal Health, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 15 Aug 2026
98 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
94
Value
93
Momentum
86
Volatility
84
Issuance
82
Quality
80
Accruals
77
Growth
61
Size
14

Revisions (94): Analysts have, on balance, been raising their forecasts.

Growth (61): Sales and profits are flat, shrinking, or growing more slowly than they were.

Size (14): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ELAN stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ELAN, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$20$25$30$35Oct 25Jan 26Apr 26Jul 26ELANHigh $34Median $32Low $26

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says17 analysts
16 Buy1 Hold0 Sell
Low $26Median $32High $34

The green dot is the last close — the median target sits +33.1% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 4 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
6 Aug 2026KeybancMaintainsOverweight$29 → $30
6 Aug 2026UBSMaintainsBuy$31 → $33
22 July 2026Morgan StanleyMaintainsEqual-Weight$23 → $26
22 July 2026Morgan StanleyMaintainsEqual-Weight—
18 June 2026TD CowenMaintainsBuy—
18 June 2026TD CowenMaintainsBuy$31 → $32
7 May 2026CitigroupMaintainsBuy—
7 May 2026JP MorganMaintainsOverweight—
15 Apr 2026CitigroupInitiatesBuy—
25 Feb 2026KeybancMaintainsOverweight—
25 Feb 2026Morgan StanleyMaintainsEqual-Weight—
24 Feb 2026Leerink PartnersMaintainsOutperform—
19 Feb 2026JP MorganMaintainsOverweight—
22 Jan 2026Piper SandlerUpgradeOverweight—
18 Dec 2025Morgan StanleyMaintainsEqual-Weight—
9 Dec 2025BarclaysInitiatesOverweight—
21 Nov 2025KeybancInitiatesOverweight—
6 Nov 2025UBSMaintainsBuy—
20 Oct 2025UBSMaintainsBuy—
7 Oct 2025JP MorganUpgradeOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ELAN appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

ELAN analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+3.5%
Analysts raising
3
Analysts cutting
0
Fundamentals

Elanco Animal Health, Inc. (ELAN) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
377.1×

Cheaper than 2% of US stocks

Price / sales
2.4×

Cheaper than 49% of US stocks

Price / book
1.8×

Cheaper than 50% of US stocks

EV / EBITDA
15.4×

Cheaper than 23% of US stocks

Growth & margins
Revenue growth (YoY)
10.2%

Higher than 53% of US stocks

Earnings growth (YoY)
390.9%

Higher than 94% of US stocks

Gross margin
58.3%

Higher than 72% of US stocks

Operating margin
8.6%

Higher than 61% of US stocks

Net margin
−4.0%

Higher than 25% of US stocks

Returns & dividend
Return on equity
−3.0%

Higher than 41% of US stocks

Return on assets
1.6%

Higher than 55% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

ELAN vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
ELANElanco Animal Health, Inc.$11.8B
98
NBIXNeurocrine Biosciences, Inc.$15.2B
89
ALKSAlkermes Plc$8.1B
60
VTRSViatris, Inc.$18.7B
100
UTHRUnited Therapeutics Corp.$21.2B
82
HIMSHims & Hers Health, Inc.$6.6B
17
LNTHLantheus Holdings, Inc.$6.5B
88

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Elanco Animal Health, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ELAN news & analysis

Elanco: Innovation Is Turning A Leveraged Portfolio Into A Share-Taking Platform

Seeking Alpha · 12 Aug 2026positive

Elanco Animal Health is transitioning from a leveraged consolidator to an innovative competitor, with new products such as Zenrelia, Credelio Quattro, and Befrena driving EBITDA growth and market share gains in dermatology and parasiticide markets, challenging Zoetis' franchises. The company is progressing on margin expansion and deleveraging through the Ascend program and strong cash flow, targeting net leverage below 3.0x by 2027.

Why it matters — ELAN watchers would care because the article indicates the company's innovation pipeline is driving market share gains against a key competitor while margin expansion and deleveraging progress toward a stated 2027 target.

Elanco Animal Health Q2 Earnings Call Highlights

MarketBeat · 8 Aug 2026positive

Elanco Animal Health reported Q2 2026 revenue of $1.368 billion, a 10% reported increase and 8% organic constant-currency growth, driven by demand for new pet-health products and strong U.S. farm animal operations.

Why it matters — The revenue beat shows Elanco's growth momentum from both its pet-health pipeline and its U.S. livestock business, two key areas investors track.

Elanco's CLiK™ Extra (dicyclanil topical suspension) Wound Spray Receives FDA Emergency Use Authorization for Application on or Around Wounds for Prevention of New World Screwworm in Variety of Livestock and Captive and Captured Wildlife Species

PRNewsWire · 7 Aug 2026positive

Elanco announced that its CLiK™ Extra wound spray received FDA Emergency Use Authorization for preventing New World screwworm in livestock and captive and captured wildlife. The company also noted it offers additional products with earlier emergency authorizations, including Negasunt® Powder and Tanidil®, as well as EPA-registered Catron™ IV.

Why it matters — The authorization expands Elanco's available tools for addressing New World screwworm infestations, adding to its portfolio of related products.

Elanco CEO on Boosted Forecast, Surge in Tick Bites

Bloomberg Markets and Finance · 6 Aug 2026positive

Elanco Animal Health President and CEO Jeff Simmons discussed the company's increased profit and revenue forecasts on "Bloomberg The Close." He also commented on a recent surge in tick bites and consumer spending on pet health products.

Why it matters — An Elanco watcher would care because the CEO cited raised profit and revenue forecasts plus tick-bite-driven demand for pet health products, which are relevant signals for the company's outlook.

ADUS vs. ELAN: Which Stock Is the Better Value Option?

Zacks Investment Research · 6 Aug 2026neutral

Zacks Investment Research published a comparison piece examining Addus HomeCare (ADUS) and Elanco Animal Health (ELAN) to determine which offers value investors a better option. The article frames the two companies as contenders for value-oriented investors but does not reach a conclusion in the provided text.

Why it matters — This piece puts Elanco in a comparative value-investing context, so ELAN watchers may gain insight into how the stock is viewed against a peer.

FAQ

Frequently asked questions about ELAN stock

What is the ELAN stock price forecast for 2026-2027?

The 17 Wall Street analysts covering Elanco Animal Health, Inc. have a median 12-month price target of $32, with estimates ranging from $26 to $34. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ELAN stock a buy right now?

Of the 17 analysts covering Elanco Animal Health, Inc., 16 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Elanco Animal Health, Inc. 98 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ELAN?

As at 15 Aug 2026, Elanco Animal Health, Inc. ranks 98 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (94 of 100).

Will ELAN stock go up?

No one can know that. What the data says: the median 12-month target from 17 analysts implies +33.1% from the last close, and Ticker Nerd's factor model ranks Elanco Animal Health, Inc. 98 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ELAN stock forecast for 2030?

No analyst covering Elanco Animal Health, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ELAN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $26 to $34 over the next 12 months.

How has ELAN stock performed over the past year?

Elanco Animal Health, Inc. returned +31.5% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Elanco Animal Health, Inc. do?

Elanco Animal Health Incorporated is a leading global pharmaceutical company specializing in animal health. Its primary function is the development and delivery of innovative products and solutions to prevent and treat diseases in both companion animals and livestock, including dogs, cats, cattle, poultry, swine, sheep, and aquaculture species.

What is the latest news on ELAN?

The most recent item we track (Seeking Alpha, 12 Aug 2026): "Elanco: Innovation Is Turning A Leveraged Portfolio Into A Share-Taking Platform". Elanco Animal Health is transitioning from a leveraged consolidator to an innovative competitor, with new products such as Zenrelia, Credelio Quattro, and Befrena driving EBITDA growth and market share gains in dermatology and parasiticide markets, challenging Zoetis' franchises. The company is progressing on margin expansion and deleveraging through the Ascend program and strong cash flow, targeting net leverage below 3.0x by 2027.

Company

About Elanco Animal Health, Inc.

Elanco Animal Health Incorporated is a leading global pharmaceutical company specializing in animal health. Its primary function is the development and delivery of innovative products and solutions to prevent and treat diseases in both companion animals and livestock, including dogs, cats, cattle, poultry, swine, sheep, and aquaculture species. With a heritage dating to 1954, Elanco combines six decades of research-driven expertise and operates across more than 90 countries, earning over half its revenue from international markets. The company serves veterinarians, farmers, and pet owners through a diverse portfolio that addresses significant animal health challenges, improving animal welfare while indirectly supporting food security and public health. Elanco’s ongoing commitment to research and sustainable practices positions it as a critical partner in enhancing animal well-being, supporting the agricultural sector, and advancing the global animal health industry.

CEO Mr. Jeffrey N. Simmons · 9,400 employees · United States · https://www.elanco.com